What is Axcella Health Inc. (AXLA)?

Axcella Health Inc. (AXLA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of AXLA?

The current price of AXLA is $4.58. Prices are updated in real time on Stocks360.

What is AXLA's price-to-earnings (PE) ratio?

AXLA's trailing twelve-month PE ratio is -3.61, based on current price and earnings per share data available on Stocks360.

What is AXLA's market capitalization?

AXLA's market capitalization is $12,503,400.00, placing it in the small-cap tier.

Axcella Health Inc. (AXLA)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.58

Market Cap

$12.50M

PE (TTM)

-3.61

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.57

Day Range

$0.36 – $4.58

52-wk Range

$0.36 – $4.58

Avg Volume

N/A

Volume

6.78K

Axcella Health Inc. (AXLA) is a publicly traded company in the Healthcare sector. Latest price: $4.58. Market cap $12.50M. Trailing PE -3.61. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 3, 2023

EPS $-1.25 vs est. $-0.06

Missed by $1.19

Proprietary Signals

Signal snapshot temporarily unavailable.

About Axcella Health Inc.

Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.61×
P/S (TTM)	0.00×
P/B	70.41×
PEG	0.07×
P/FCF (TTM)	-0.18×
EV / EBITDA	0.03×
EV / Sales	0.00×
Earnings Yield	-27.69%
Free Cash Flow Yield	-559.96%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$2.48M
Net Income (TTM)	-$3.46M
Free Cash Flow (TTM)	-$66.99M
Net Debt	-$14.99M
Working Capital	$3.00M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-620.40%
Return on Invested Capital	-1142.66%